This compound is a quinazoline diamine derivative featuring fluorine and ether substituents, used as a pharmaceutical intermediate in the manufacturing of afatinib.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2044709-72-8
N4-(3-chloro-4-fluorophenyl)-7-(((3S)-tetrahydro-3-furanyl)oxy)-4,6-quinazolinediamine
pharmaceutical raw material
(R)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diamine
pharmaceutical raw material
(S)-N4-(4-Fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine (Afatinib Impurity)
pharmaceutical raw material
(S)-N4-(3,4-Dichlorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine
pharmaceutical intermediate
Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate
pharmaceutical intermediate
1-Bromo-3,5-dimethoxybenzene
pharmaceutical intermediate
N-Fmoc-N'-[1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-lysine
pharmaceutical intermediate
6-(Benzyloxy)-9-[(1S,3R,4S)-2-methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclopentyl]-9H-purine-2-amine
pharmaceutical intermediate
4-N-(3,4-difluorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine
XGUCTFIMQFLKRU-NSHDSACASA-N
C1COC[C@H]1OC2=C(C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)F)F)N